In a 23-patient study, the company’s NYX-2925 drug led to a significant impact on brain activity associated with processing pain in patients with fibromyalgia. Patients also self-reported lower pain scores and improved on other fibromyalgia symptom scales.
Shares jumped 12% to $3.40 Wednesday afternoon.
READ: Aptinyx stock falls after NYX-2925 trial for treating painful diabetic nerve damage fails to meet endpoint
Based on the results, the Evanston, Illinois-based company will begin a larger 12-week study later in 2019.
Fibromyalgia is a chronic pain condition that affects the central nervous system. NYX-2925 is also used to treat Diabetic Peripheral Neuropathy, nerve damage associated with high blood sugar and diabetes. The drug earned Fast Track designation for treatment from DPN from the Food and Drug Administration.
“The statistically significant effects on both pain-related brain activity and patient-reported clinical measures elegantly demonstrates that NYX-2925 is acting in the brain to alter pain processing, leading to pain alleviation,” CEO Norbert Riedel said. “The consistency of these data confirms our confidence in advancing NYX-2925 as a treatment for chronic pain. We look forward to initiating follow-up studies in both painful DPN and fibromyalgia later this year.”
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel